Connective tissue growth factor reacts as an IL - World Journal of ...
Connective tissue growth factor reacts as an IL - World Journal of ...
Connective tissue growth factor reacts as an IL - World Journal of ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
play <strong>an</strong> import<strong>an</strong>t role in <strong>an</strong>giogenesis. G<strong>as</strong>troenterop<strong>an</strong>creatic neuroendocrine<br />
tumors (GEP-NETs) are rare <strong>an</strong>d heterogeneous. Although markers for GEP-<br />
NETs exist, sensitive <strong>an</strong>d specific markers that indicate tumor <strong>growth</strong> <strong>an</strong>d behavior<br />
are lacking.<br />
Research frontiers<br />
The aim <strong>of</strong> the present study w<strong>as</strong> to evaluate the expression <strong>an</strong>d potential<br />
prognostic role <strong>of</strong> VEGF <strong>an</strong>d endoglin in GEP-NETs.<br />
Innovations <strong>an</strong>d breakthroughs<br />
From other studies it is already known that GEP-NETs are highly v<strong>as</strong>cularized<br />
tumors. Although several studies have investigated the immunohistochemical<br />
expression VEGF in GEP-NETs, VEGF <strong>tissue</strong> levels or endoglin expression<br />
have not been studied in these tumors before. Therefore, this study is believed<br />
to be the first to investigate <strong>tissue</strong> expression <strong>an</strong>d levels <strong>of</strong> VEGF <strong>an</strong>d endoglin<br />
in GEP-NETs, to determine the clinical impact <strong>of</strong> these <strong>an</strong>giogenic <strong>factor</strong>s in<br />
patients with GEP-NETs.<br />
Applications<br />
B<strong>as</strong>ed on our findings, we suggest that endoglin is a potential marker to indicate<br />
the presence <strong>of</strong> met<strong>as</strong>t<strong>as</strong>es in GEP-NETs. By demonstrating that incre<strong>as</strong>ed<br />
endoglin expression on tumors is related to tumor aggressiveness (including<br />
grade <strong>of</strong> differentiation, size <strong>an</strong>d presence <strong>of</strong> met<strong>as</strong>t<strong>as</strong>es), this study could present<br />
a future target for post-resection therapeutic intervention in the treatment <strong>of</strong><br />
patients with GEP-NETs.<br />
Terminology<br />
Angiogenesis is the process <strong>of</strong> new blood vessel formation. This process is induced<br />
by several <strong>growth</strong> <strong>factor</strong>s, including VEGF, <strong>an</strong>d tr<strong>an</strong>sforming <strong>growth</strong> <strong>factor</strong><br />
(TGF)-β1. Endoglin is a co-receptor for TGF-β1 <strong>an</strong>d a marker for <strong>an</strong>giogenic<br />
endothelial cells.<br />
Peer review<br />
This is a well-written paper that describes a study that evaluated the expression<br />
<strong>an</strong>d potential prognostic role <strong>of</strong> VEGF <strong>an</strong>d endoglin in a small sample <strong>of</strong> GEP-<br />
NETs patients, <strong>an</strong>d is <strong>of</strong> considerable interest.<br />
REFERENCES<br />
1 Barakat MT, Meer<strong>an</strong> K, Bloom SR. Neuroendocrine tumours.<br />
Endocr Relat C<strong>an</strong>cer 2004; 11: 1-18<br />
2 Poncet G, Villaume K, Walter T, Pourreyron C, Theillaum<strong>as</strong> A,<br />
Lépin<strong>as</strong>se F, Hervieu V, Cordier-Bussat M, Scoazec JY, Roche C.<br />
Angiogenesis <strong>an</strong>d tumor progression in neuroendocrine digestive<br />
tumors. J Surg Res 2009; 154: 68-77<br />
3 Folkm<strong>an</strong> J. Tumor <strong>an</strong>giogenesis. Adv C<strong>an</strong>cer Res 1974; 19:<br />
331-358<br />
4 Veikkola T, Alitalo K. VEGFs, receptors <strong>an</strong>d <strong>an</strong>giogenesis.<br />
Semin C<strong>an</strong>cer Biol 1999; 9: 211-220<br />
5 Strosberg JR, Kvols LK. A review <strong>of</strong> the current clinical trials<br />
for g<strong>as</strong>troenterop<strong>an</strong>creatic neuroendocrine tumours. Expert<br />
Opin Investig Drugs 2007; 16: 219-224<br />
6 Yao JC, Ph<strong>an</strong> A, H<strong>of</strong>f PM, Chen HX, Charns<strong>an</strong>gavej C, Yeung<br />
SC, Hess K, Ng C, Abbruzzese JL, Aj<strong>an</strong>i JA. Targeting v<strong>as</strong>cular<br />
endothelial <strong>growth</strong> <strong>factor</strong> in adv<strong>an</strong>ced carcinoid tumor: a<br />
r<strong>an</strong>dom <strong>as</strong>signment ph<strong>as</strong>e II study <strong>of</strong> depot octreotide with<br />
bevacizumab <strong>an</strong>d pegylated interferon alpha-2b. J Clin Oncol<br />
2008; 26: 1316-1323<br />
7 Hawinkels LJ, Verspaget HW, v<strong>an</strong> Duijn W, v<strong>an</strong> der Zon JM,<br />
Zuidwijk K, Kubben FJ, Verheijen JH, Hommes DW, Lamers<br />
CB, Sier CF. Tissue level, activation <strong>an</strong>d cellular localisation<br />
<strong>of</strong> TGF-beta1 <strong>an</strong>d <strong>as</strong>sociation with survival in g<strong>as</strong>tric c<strong>an</strong>cer<br />
patients. Br J C<strong>an</strong>cer 2007; 97: 398-404<br />
8 Li C, Guo B, Bernabeu C, Kumar S. Angiogenesis in bre<strong>as</strong>t<br />
c<strong>an</strong>cer: the role <strong>of</strong> tr<strong>an</strong>sforming <strong>growth</strong> <strong>factor</strong> beta <strong>an</strong>d CD105.<br />
Microsc Res Tech 2001; 52: 437-449<br />
9 Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin<br />
(CD105): a powerful therapeutic target on tumor-<strong>as</strong>sociated<br />
<strong>an</strong>giogenetic blood vessels. Oncogene 2003; 22: 6557-6563<br />
WJG|www.wjgnet.com<br />
Kuiper P et al . Angiogenic markers in neuroendocrine tumors<br />
10 Zijlm<strong>an</strong>s HJ, Fleuren GJ, Hazelbag S, Sier CF, Dreef EJ,<br />
Kenter GG, Gorter A. Expression <strong>of</strong> endoglin (CD105) in cervical<br />
c<strong>an</strong>cer. Br J C<strong>an</strong>cer 2009; 100: 1617-1626<br />
11 Yoshitomi H, Kobay<strong>as</strong>hi S, Ohtsuka M, Kimura F, Shimizu H,<br />
Yoshidome H, Miyazaki M. Specific expression <strong>of</strong> endoglin<br />
(CD105) in endothelial cells <strong>of</strong> intratumoral blood <strong>an</strong>d lymphatic<br />
vessels in p<strong>an</strong>creatic c<strong>an</strong>cer. P<strong>an</strong>cre<strong>as</strong> 2008; 37: 275-281<br />
12 Rom<strong>an</strong>i AA, Borghetti AF, Del Rio P, Si<strong>an</strong>esi M, Soli<strong>an</strong>i P. The<br />
risk <strong>of</strong> developing met<strong>as</strong>tatic dise<strong>as</strong>e in colorectal c<strong>an</strong>cer is<br />
related to CD105-positive vessel count. J Surg Oncol 2006; 93:<br />
446-455<br />
13 Rindi G, Klöppel G. Endocrine tumors <strong>of</strong> the gut <strong>an</strong>d p<strong>an</strong>cre<strong>as</strong><br />
tumor biology <strong>an</strong>d cl<strong>as</strong>sification. Neuroendocrinology 2004;<br />
80 Suppl 1: 12-15<br />
14 Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu<br />
Z, Pardali E, Sier CF, ten Dijke P. Matrix metalloprotein<strong>as</strong>e-14<br />
(MT1-MMP)-mediated endoglin shedding inhibits tumor <strong>an</strong>giogenesis.<br />
C<strong>an</strong>cer Res 2010; 70: 4141-4150<br />
15 Lowry OH, Rosebrough NJ, Farr AL, RANDALL RJ. Protein<br />
me<strong>as</strong>urement with the Folin phenol reagent. J Biol Chem 1951;<br />
193: 265-275<br />
16 Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller<br />
ES, v<strong>an</strong> Duijn W, Ferreira V, Fontijn RD, David G, Hommes<br />
DW, Lamers CB, Sier CF. VEGF rele<strong>as</strong>e by MMP-9 mediated<br />
hepar<strong>an</strong> sulphate cleavage induces colorectal c<strong>an</strong>cer <strong>an</strong>giogenesis.<br />
Eur J C<strong>an</strong>cer 2008; 44: 1904-1913<br />
17 Quesada AR, Muñoz-Chápuli R, Medina MA. Anti-<strong>an</strong>giogenic<br />
drugs: from bench to clinical trials. Med Res Rev 2006;<br />
26: 483-530<br />
18 Nussenbaum F, Herm<strong>an</strong> IM. Tumor <strong>an</strong>giogenesis: insights<br />
<strong>an</strong>d innovations. J Oncol 2010; 2010: 132641<br />
19 Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkm<strong>an</strong> J.<br />
Tumor <strong>an</strong>giogenesis correlates with met<strong>as</strong>t<strong>as</strong>is in inv<strong>as</strong>ive<br />
prostate carcinoma. Am J Pathol 1993; 143: 401-409<br />
20 Weidner N, Semple JP, Welch WR, Folkm<strong>an</strong> J. Tumor <strong>an</strong>giogenesis<br />
<strong>an</strong>d met<strong>as</strong>t<strong>as</strong>is--correlation in inv<strong>as</strong>ive bre<strong>as</strong>t carcinoma.<br />
N Engl J Med 1991; 324: 1-8<br />
21 Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M.<br />
Targeting c<strong>an</strong>cer v<strong>as</strong>culature via endoglin/CD105: a novel<br />
<strong>an</strong>tibody-b<strong>as</strong>ed diagnostic <strong>an</strong>d therapeutic strategy in solid<br />
tumours. Cardiov<strong>as</strong>c Res 2010; 86: 12-19<br />
22 Zh<strong>an</strong>g J, Jia Z, Li Q, W<strong>an</strong>g L, R<strong>as</strong>hid A, Zhu Z, Ev<strong>an</strong>s DB,<br />
Vauthey JN, Xie K, Yao JC. Elevated expression <strong>of</strong> v<strong>as</strong>cular endothelial<br />
<strong>growth</strong> <strong>factor</strong> correlates with incre<strong>as</strong>ed <strong>an</strong>giogenesis<br />
<strong>an</strong>d decre<strong>as</strong>ed progression-free survival among patients with<br />
low-grade neuroendocrine tumors. C<strong>an</strong>cer 2007; 109: 1478-1486<br />
23 Takah<strong>as</strong>hi Y, Akishima-Fuk<strong>as</strong>awa Y, Kobay<strong>as</strong>hi N, S<strong>an</strong>o T,<br />
Kosuge T, Nimura Y, K<strong>an</strong>ai Y, Hiraoka N. Prognostic value<br />
<strong>of</strong> tumor architecture, tumor-<strong>as</strong>sociated v<strong>as</strong>cular characteristics,<br />
<strong>an</strong>d expression <strong>of</strong> <strong>an</strong>giogenic molecules in p<strong>an</strong>creatic<br />
endocrine tumors. Clin C<strong>an</strong>cer Res 2007; 13: 187-196<br />
24 Bierie B, Moses HL. Tumour microenvironment: TGFbeta:<br />
the molecular Jekyll <strong>an</strong>d Hyde <strong>of</strong> c<strong>an</strong>cer. Nat Rev C<strong>an</strong>cer 2006;<br />
6: 506-520<br />
25 Bernabeu C, Lopez-Novoa JM, Quint<strong>an</strong>illa M. The emerging<br />
role <strong>of</strong> TGF-beta superfamily coreceptors in c<strong>an</strong>cer. Biochim<br />
Biophys Acta 2009; 1792: 954-973<br />
26 Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW,<br />
Thakker RV, Caplin M, Delle Fave G, Kalts<strong>as</strong> GA, Krenning<br />
EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P,<br />
Sundin A. G<strong>as</strong>troenterop<strong>an</strong>creatic neuroendocrine tumours.<br />
L<strong>an</strong>cet Oncol 2008; 9: 61-72<br />
27 Metz DC, Jensen RT. G<strong>as</strong>trointestinal neuroendocrine tumors:<br />
p<strong>an</strong>creatic endocrine tumors. G<strong>as</strong>troenterology 2008; 135:<br />
1469-1492<br />
S- Editor Sun H L- Editor Kerr C E- Editor Zheng XM<br />
225 J<strong>an</strong>uary 14, 2011|Volume 17|Issue 2|
Change language